IONIS PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Private, Subsidiary
- Established
- 1989-01-01
- Employees
- 927
- Market Cap
- -
- Website
- http://www.ionis.fr
Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).
- Conditions
- Interventions
- First Posted Date
- 2018-11-02
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT03728634
- Locations
- 🇨🇦
Bio Pharma Services, Inc., Toronto, Ontario, Canada
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT03714776
- Locations
- 🇺🇸
Ohio Clinical Research - Lyndhurst, Lyndhurst, Ohio, United States
🇺🇸Orange County Research Center, Tustin, California, United States
🇺🇸Progressive Medical Research, Port Orange, Florida, United States
A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT03647228
- Locations
- 🇩🇪
Universitätsmedizin Essen, Essen, Germany
🇩🇪Lungenheilkunde München-Pasing, München, Germany
🇬🇧Western General Hospital, Edinburgh, United Kingdom
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of IONIS FXI-LRx in up to 84 Healthy Volunteers
- First Posted Date
- 2018-07-11
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT03582462
- Locations
- 🇨🇦
BioPharma Services Inc., Toronto, Ontario, Canada
Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT03548415
- Locations
- 🇺🇸
University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States
🇺🇸St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
- Conditions
- Interventions
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Registration Number
- NCT03446144
- Locations
- 🇦🇺
Sydney Retina Clinic Day Surgery, Sydney, New South Wales, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Lions Eye Institute, Nedlands, Western Australia, Australia
ATTR Expanded Access Program (EAP) by Ionis
- Conditions
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Registration Number
- NCT03400098
A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 213
- Registration Number
- NCT03358030
- Locations
- 🇪🇸
Ionis Investigative Site, Alcalá De Henares, Madrid, Spain
Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT03334214
- Locations
- 🇬🇧
Ionis Investigational Site, Nottingham, United Kingdom
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen (IONIS-PKK-LRx) Administered Subcutaneously to Healthy Volunteers
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03263507
- Locations
- 🇨🇦
Ionis Investigative Site, Toronto, Ontario, Canada